FOLLOW THE $$
San Francisco Business Times - by Ron Leuty
Date: Friday, December 31, 2010, 3:00am PSTBiotech: Pill to watch-Gilead Sciences' Quad pill
Foster City-based Gilead could change the game for HIV patients and its bottom line, adding a new drug and booster to its once-a-day pill.
The so-called Quad pill and its elements are undergoing three Phase III studies. A fourth 700-patient trial is enrolling.
About half of the HIV patients who start therapy in the United States already use Gilead’s three-in-one Atripla, which uses Bristol-Myers Squibb’s Sustiva. The Quad pill drops the Bristol-Myers Squibb drug and uses Viread, Emtriva and a new Gilead drug called elvitegravir plus an elvitegravir booster.
Wall Street analysts have pegged the pill as a $4 billion-a-year ...Read more: Biotech: Pill to watch-Gilead Sciences' Quad pill | San Francisco Business Times
No comments:
Post a Comment